| Title |
Publication Date |
Price |
Relevance |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£8000 |
100 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
98 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
97 % |
OncoVista Innovative Therapies, Inc.-Therapeutic Competitors
|
January 2010 |
£225 |
46.5 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
45 % |
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
|
August 2007 |
£7600 |
41.5 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
38.5 % |
Analytical Tool - Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2705 |
38 % |
Stakeholder Opinions: Bladder Cancer
New drugs needed to challenge ineffective 20 year old drugs
|
November 2008 |
£2000 |
37.5 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
36 % |
Stakeholder Insight: COPD - Another Reason to Quit
|
December 2005 |
£8695 |
36 % |
Myelodysplastic Syndromes - First Approvals Spur Some Interest In A Niche Market
Stakeholder Opinions
|
December 2007 |
£2005 |
35 % |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2005 |
34.5 % |
Breast Cancer - Therapeutic And Competitive Insights
|
February 2007 |
£1360 |
34 % |
Breast Cancer
Therapeutic And Competitive Insights
|
February 2007 |
£1360 |
34 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1430 |
33.5 % |
World Market for Addiction Disorders 2005-2012, The
New Horizons in High-Profile Dependency Markets
|
December 2005 |
£1100 |
33 % |
Stem Cell Research
Market Trends, Investment Trends and Pipeline Analysis
|
February 2010 |
£2230 |
32.5 % |
Arena Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£80 |
30.5 % |
InterMune, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£80 |
30.5 % |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1700 |
30.5 % |
World Market for Addiction Disorders, 2009 - 2016
The Future Therapies for Substance Dependence and Impulse Control
|
October 2009 |
£1495 |
29.5 % |
Partnering Agreements with Amgen 2010
|
January 2010 |
£295 |
29 % |
Partnering Agreements with Allergan 2010
|
January 2010 |
£295 |
29 % |
Partnering Agreements with Alcon 2010
|
January 2010 |
£295 |
29 % |
Monoclonal Antibodies 2007
Competitive Landscape & Pipeline Insight
|
January 2007 |
£1430 |
27.5 % |
Pipeline Insight: Colorectal Cancer
Growing trend towards personalized medicine
|
October 2010 |
£11400 |
27.3 % |
Stakeholder Perspectives: Pulmonary Arterial Hypertension
A small market gets big attention
|
February 2006 |
£4350 |
27 % |
Prostate and Breast Cancer
New Treatments & Developmental Progress
|
March 2007 |
£2060 |
26.5 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£3010 |
26.5 % |
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics
|
August 2007 |
£6000 |
25.2 % |
Substance Dependence - Part II: Alcohol
Pipeline Insight
|
December 2007 |
£3800 |
24.5 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£3010 |
24.5 % |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2575 |
24 % |
Partnering Agreements with Actavis 2010
|
January 2010 |
£295 |
24 % |
Partnering Agreements with Abbott 2010
|
January 2010 |
£295 |
24 % |
Partnering Agreements with UCB 2010
|
January 2010 |
£295 |
24 % |
Stada Partnering Guide 2008
|
July 2008 |
£195 |
24 % |
Partnering Agreements with CSL 2010
|
January 2010 |
£295 |
24 % |
Wyeth Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Teva 2010
|
January 2010 |
£295 |
23.5 % |
Mundipharma Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Takeda 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Solvay 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Novo Nordisk 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Nycomed 2010
|
January 2010 |
£295 |
23.5 % |
Barr Pharmaceuticals Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
ScheringPlough Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Allergan Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Watson 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Otsuka 2010
|
January 2010 |
£295 |
23.5 % |
Amgen Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
GlaxoSmithKline Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
ProcterGamble Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
King Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Shire 2010
|
January 2010 |
£295 |
23.5 % |
Abbott Labs Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Mitsubishi Tanabe 2010
|
January 2010 |
£295 |
23.5 % |
Actavis Pharma Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Partnering Agreements with Ratiopharm 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Bayer 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Baxter 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Biogen Idec 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Bristol-Myers Squibb 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Chugai 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Cephalon 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Dainippon Sumitomo 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with AstraZeneca 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Astellas 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Forest 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Daiichi Sankyo 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Mylan 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Servier 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Eli Lilly 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Eisai 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Roche 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Boehringer Ingelheim 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Pfizer 2010
|
January 2010 |
£295 |
23.5 % |
Partnering Agreements with Novartis 2010
|
January 2010 |
£295 |
23.5 % |
Alcon Labs Partnering Guide 2008
|
July 2008 |
£195 |
23.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£2410 |
23.5 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
23.45 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
23.45 % |
Stakeholder Opinions: Gastric Cancer
Targeted Therapies Home In On a Neglected Tumor Type
|
March 2006 |
£2195 |
23.45 % |
Analytical Tool - Hematological Cancers
|
May 2007 |
£5190 |
23 % |
Partnering Agreements with Sanofi-Aventis 2010
|
January 2010 |
£295 |
23 % |
Lorus Therapeutics Inc - Financial and Strategic Analysis Review
|
April 2009 |
£80 |
23 % |
Endometriosis - Scientific Clarity Will Unlock Market Potential Stakeholder Opinions
|
December 2007 |
£2005 |
22.4 % |
Pipeline Insight: Acute Stroke
Commercial Risk Offsets High Unmet Need
|
May 2008 |
£6000 |
22.4 % |
Analytical Tool - Lymphoma Therapeutics & Competitive Insights
|
May 2007 |
£2705 |
21.5 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
21.35 % |
Hepatitis C - Small-Molecule Antivirals Pave The Way For Triple Therapy
Stakeholder Opinions
|
December 2007 |
£2005 |
21.35 % |
Partnering with Biopharma
The definitive guide to bigpharma partnering interests, contacts & agreements
|
July 2008 |
£1495 |
21 % |
Pipeline Insight: Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
December 2006 |
£6000 |
20.65 % |
Stakeholder Opinions: Osteoarthritis
Preconceptions Damage Awareness and Treatments
|
March 2006 |
£2195 |
20 % |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
19.95 % |
Pipeline Insight: Insulins
Inhalable insulins unlikely to become blockbusters
|
September 2006 |
£6000 |
19.6 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£3010 |
19.5 % |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2005 |
19.25 % |
Commercial Insight: Multiple Sclerosis
Continued growth makes the MS market a highly attractive investment
|
June 2007 |
£7600 |
18.9 % |
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs
Healthcare
|
March 2009 |
£2000 |
18.9 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£1499 |
18.5 % |
Stakeholder Opinions: Biologics in Infectious Diseases
Well Defined Target Populations Are Key to Commercial Success
|
March 2008 |
£2005 |
17.85 % |
The Cardiovascular Disorders Market Outlook to 2012
|
February 2008 |
£1995 |
17.5 % |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
December 2006 |
£6000 |
17.5 % |
Pipeline Insight: Neuropathic Pain
Emerging Drugs Fail To Capitalize In Lucrative Market
|
September 2007 |
£740 |
17.5 % |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
17.5 % |
Pipeline Insight: Antiarrhythmics
RSD1235 in a class of its own
|
May 2006 |
£6495 |
17.5 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
17.5 % |
Stakeholder Opinion: Atopic Dermatitis
A high level of unmet need creates market opportunities
|
March 2007 |
£2005 |
17.5 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
17.15 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£6000 |
16.8 % |
Commercial and Pipeline Insight: Psoriasis
Anti-TNF's lead another indication
|
December 2006 |
£8000 |
16.8 % |
Stakeholder Opinions: Systemic Lupus Erythematosus
Market Set to Enter Era of Biologic Therapies
|
March 2008 |
£2050 |
16.45 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
16.1 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
16.1 % |
Pipeline Insight: Insulin Antidiabetics
Return to Injections Alternative Delivery Methods Fall by The Wayside
|
July 2008 |
£6000 |
16.1 % |
Anticoagulants
A Global Market Review
|
November 2009 |
£1905 |
15.75 % |
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Healthcare
|
March 2009 |
£2000 |
15.75 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1700 |
15.5 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£3085 |
15.5 % |
Management of Urinary Incontinence and Overactive Bladder
A Global Overview
|
June 2006 |
£8695 |
15.05 % |
Stakeholder Opinions: Skin and soft tissue infections
|
July 2009 |
£3800 |
15.05 % |
Stakeholder Opinions: Fibromyalgia
Potentially lucrative market soon to become reality
|
May 2007 |
£2005 |
14.7 % |
Pipeline Insight: Non-insulin Antidiabetics
Type 2 diabetes unlikely to develop into a switch market
|
August 2006 |
£6495 |
14.7 % |
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease
|
November 2007 |
£3800 |
14.7 % |
Pipeline Insight: Epilepsy
Pipeline drugs struggle to outshine their marketed predecessors
|
October 2006 |
£6000 |
14.7 % |
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth
|
October 2008 |
£8000 |
14.7 % |
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis
|
November 2008 |
£6000 |
14.7 % |
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline
|
May 2008 |
£6000 |
14.35 % |
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success
Healthcare
|
March 2009 |
£2000 |
14.35 % |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
14 % |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
|
March 2008 |
£7600 |
14 % |
Stakeholder Opinions: Cystic Fibrosis
|
March 2006 |
£2195 |
13.65 % |
Commercial Insight: Migraine
Opportunities Will Exist In The Wake Of Generic Attack
|
September 2007 |
£7600 |
13.65 % |
Stakeholder Insight: Chronic Leukemias
Is there room left for improvement?
|
November 2008 |
£8000 |
13.65 % |
Commercial and Pipeline Insight: Hepatitis B
|
October 2007 |
£7600 |
13.65 % |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
13.65 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
13.5 % |
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth
|
April 2009 |
£6000 |
13.3 % |
Stakeholder Opinions: Asthma Phenotypes A changing paradigm
|
March 2007 |
£2005 |
13.3 % |
Lung Cancer Therapeutics
|
July 2009 |
£2515 |
13.3 % |
Pipeline and Commercial Insight: Alzheimer's Disease
Scenario Forecasts Reveal Vast Market Potential
|
March 2008 |
£7600 |
12.95 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
12.6 % |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2005 |
12.6 % |
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
|
February 2009 |
£3010 |
12.25 % |
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope
Healthcare
|
March 2009 |
£2000 |
12.25 % |
Shire plc: PharmaVitae Profile
|
November 2008 |
£3010 |
12.25 % |
Stakeholder Opinions: Bone Metastases
Impending Patent Expiries May Help Make or Break Newer Agents
|
March 2008 |
£2005 |
11.9 % |
Forecast Insight: Multiple Sclerosis
Tysabri to prevail despite safety setbacks
|
August 2008 |
£7600 |
11.55 % |
Stakeholder Opinions: Cancer Cachexia
Higher profile needed to unlock market potential of neglected syndrome
|
January 2009 |
£2000 |
11.2 % |
Commercial Insight: Neuropathic Pain
A Plethora of Patient Segmentation and Product Differentiation Opportunities
|
July 2006 |
£8440 |
11.2 % |
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome
Reformulations set to drive near-term growth
|
August 2006 |
£8695 |
11.2 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
11.2 % |
Commercial and Pipeline Insight: ADHD
Immature adult market continues to offer greatest commercial potential
|
April 2008 |
£8000 |
10.85 % |
Pipeline and Commercial Insight: Osteoporosis
Novel agents to battle for payer acceptance
|
July 2009 |
£15200 |
10.85 % |
Merck KGaA: PharmaVitae Profile
|
March 2009 |
£3010 |
10.85 % |
Merck & Co. Inc: PharmaVitae Profile
|
July 2009 |
£5700 |
10.5 % |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
10.5 % |
Genzyme Corporation: PharmaVitae Profile
|
March 2009 |
£3010 |
10.5 % |
Stakeholder Insight
Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma
|
July 2008 |
£7600 |
10.15 % |
Abbott Laboratories: PharmaVitae Profile
Healthcare
|
September 2009 |
£5700 |
9.45 % |
Diabetes Drug Discoveries 2009: what the future holds
|
February 2009 |
£795 |
9.45 % |
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential
Healthcare
|
March 2009 |
£8000 |
9.45 % |
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life
Healthcare
|
March 2009 |
£2000 |
9.1 % |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
9.1 % |
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies
|
November 2008 |
£8000 |
9.1 % |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
8.75 % |
Commercial Insight: Epilepsy
Companies Committed To The Cause Will Reap The Benefits
|
September 2007 |
£7600 |
8.05 % |
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
|
July 2007 |
£7600 |
8.05 % |
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus
Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts
|
August 2008 |
£7600 |
7.7 % |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
7.35 % |
Commercial Insight: Asthma & COPD
Combination Products Still Have Blockbuster Potential
|
July 2007 |
£7600 |
5.25 % |
